Homepage > Company > Media > Pharma News > 2018 > AstraZeneca diabetes drug cuts heart risks in major study

AstraZeneca diabetes drug cuts heart risks in major study

LONDON (Reuters) - AstraZeneca said on Monday its diabetes drug Farxiga met a key goal in a major clinical study designed to show the heart-protecting benefits of the medicine.

Diabetics are at increased risk of heart problems, making the cardiovascular (CV) profile of medicines to treat the condition a key focus for doctors and patients.

In the 17,000-patient trial known as Declare, patients on Farxiga achieved a statistically-significant and clinically-important reduction in hospitalization for heart failure or CV death compared with those on placebo, the company said.

There were also fewer major adverse cardiovascular events, although in this case the difference did not reach statistical significance.

Full results from the Declare study will be presented on Nov. 10 at the annual meeting of the American Heart Association.

Farxiga competes with rival diabetes drugs such as Eli Lilly’s Jardiance and Novo Nordisk’s Victoza, which has already shown certain heart benefits.

SEPTEMBER 24, 2018

https://www.reuters.com/

Read also

FDA warns vs fake versions of popular medicines

MANILA, Philippines - counterfeit versions of some popular over-the-counter pain relievers and flu medicines are circulating in the market, the Food and Drug Administration (FDA) reported. ...

Japan's Eisai inks $2 B oncology deal with China-based startup Bliss Biopharma

Cognixion, a developer of non-invasive Brain-Computer Interface (BCI) and Augmented Reality (AR) technology, has announced that the US Food and Drug Administration (FDA) has granted its device Brea...

Cognixion receives FDA Breakthrough Device Designation for assisted communication device

EMA to review CTIS transparency rules

Public consultation seeks the best methods for balancing transparency with confidentiality in the EU Clinical Trials Information System, says the European Medicines Agency. ...